Parosteal Osteosarcoma
Parosteal Osteosarcoma
Clinical Scenario
An 18-year-old female presents with a slowly enlarging painless mass on the posterior aspect of her right distal thigh. She first noticed it 2 years ago when it was small, and it has gradually increased in size. There is now mild discomfort with prolonged sitting.
History:
- 2-year history of posterior thigh mass
- Slow, painless enlargement
- Now causing mild discomfort with sitting
- No trauma history
- No constitutional symptoms
- No family history of bone tumours
- Otherwise fit and well, university student
Examination Findings:
- 8 x 6 cm firm, non-tender mass posterior distal thigh
- Fixed to deep structures, limited mobility
- Skin normal, no overlying changes
- No regional lymphadenopathy
- Full knee range of motion
- Normal neurovascular examination
- Normal gait
- Contralateral limb normal
Investigations
Laboratory Results
Imaging
Plain X-ray Right Femur (AP and Lateral):
- Densely mineralised, lobulated mass arising from posterior femoral cortex
- 'String sign' - radiolucent line separating mass from cortex
- Mass appears to wrap around femur ('stuck-on' appearance)
- Dense, homogeneous ossification (mature bone)
- No periosteal reaction
- No cortical destruction
- Medullary canal appears uninvolved
MRI Right Femur with Gadolinium:
- 8.2 x 5.5 x 4.8 cm lobulated surface mass
- Predominantly low T1 and T2 signal (mature bone)
- Thin rim of high T2 signal at periphery (cartilage cap ~3mm)
- String sign confirmed - thin plane between mass and cortex
- No medullary involvement (critical finding)
- Mass wraps around 60% of femoral circumference
- Popliteal vessels displaced posteriorly but not encased
- No heterogeneous high-grade areas
CT Chest (Staging):
- No pulmonary metastases
- No mediastinal lymphadenopathy
Histopathology
Core Needle Biopsy Result:
- Well-differentiated osteosarcoma, low-grade
- Mature bone trabeculae with bland spindle cells
- Minimal atypia, low mitotic rate
- Parallel bone formation (organised pattern)
- Fibrous component with streaming spindle cells
- No high-grade/dedifferentiated areas in this sample
- FISH: MDM2 and CDK4 amplification positive
- Diagnosis: Parosteal osteosarcoma, low-grade
Questions & Model Answers
What is the diagnosis and how does it differ from conventional osteosarcoma?
Describe the spectrum of surface osteosarcomas and their key differences.
What are the risks of dedifferentiation and how does this affect management?
What is your surgical approach for this patient's tumour?
How would you differentiate parosteal osteosarcoma from myositis ossificans and osteochondroma on imaging?
What is the prognosis and follow-up protocol for this patient?
Key Teaching Points
| Concept | Detail |
|---|---|
| Definition | Low-grade surface osteosarcoma from periosteum |
| Classic Location | Posterior distal femur (70%) |
| Demographics | Young adults (25-30), female predominance |
| String Sign | Radiolucent line between tumour and cortex |
| Genetic Marker | MDM2 and CDK4 amplification |
| Treatment | Wide resection alone (no chemo for pure low-grade) |
| Dedifferentiation | 15-20% - changes to high-grade behaviour |
| Prognosis | Excellent: 90-95% 5-year survival |
Common Examiner Follow-up Questions
-
"What is the difference between parosteal and periosteal osteosarcoma?"
- Parosteal: low-grade, dense ossification, posterior metaphysis
- Periosteal: intermediate-grade, chondroblastic, diaphysis, perpendicular spicules
- Both are surface tumours with better prognosis than conventional
-
"What if the tumour encases the popliteal vessels?"
- Preoperative angiography/CT angiography
- Vascular surgery involvement
- May need vessel resection and reconstruction
- If reconstruction not possible, amputation may be required
-
"How do you confirm the diagnosis if imaging is equivocal?"
- CT-guided core biopsy
- FISH for MDM2/CDK4 amplification
- Serial imaging if myositis ossificans suspected
- Myositis ossificans matures over 6-8 weeks
-
"What chemotherapy regimen is used for dedifferentiated parosteal OS?"
- Same as conventional high-grade OS
- MAP protocol: Methotrexate, Adriamycin (doxorubicin), cisPlatin
- Neoadjuvant + adjuvant
- Assess histological necrosis post-neoadjuvant